Prostate Cancer

In the first interview of the series, Nilay Gandhi, MD, provides an overview of advanced/metastatic prostate cancer and the role of androgen deprivation therapy in treating patients.

Key opinion leaders discuss how PSMA PET CT tracers, including gallium 68 and fluorine 18, are revolutionizing prostate cancer patient management and with accurate and early detection of disease spread.

A review of available PSMA PET tracers for prostate cancer detection, covering sensitivity, specificity, access to therapy, and reimbursement impacting patient care.

"FPSA is an important, inexpensive, and readily available test in our risk-stratification toolbox," writes Badar M. Mian, MD.

In the third article of this series, Amar U. Kishan, MD, provides clinical insights on the use of perirectal spacers for patients who receive hypofractionated radiation or SBRT.

"This could make a huge impact for patients with limited resources,” says Benjamin Pockros, MD, MBA.

"Encouraging our patients to adopt a healthy, plant-based diet is a great way to simultaneously promote both prostate and overall health," writes Stacy Loeb, MD, MSc.

Shared insight into FDA-approved PSMA PET imaging tracers, highlighting similarities and differences between gallium 68 and fluorine 18 compounds.

Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, delve into patient selection for PSMA PET CT scans, discussing indications spanning initial diagnosis and recurrence, as well as institution guidelines.

Men who had a dorsal testosterone/peripheral testosterone ratio greater than 2 were found to have higher rates of PSA persistence compared with patients who had a similar ratio.

The published findings show the viability of using a transperineal ultrasound system as a means to monitor intra-fractional prostate motion for prostate stereotactic body radiotherapy.

Experts explore PSMA's significance in prostate cancer imaging, covering its expression, limitations, and transformative role in detecting even low PSA recurrences with PSMA-PET technology.

In this introductory dialogue, Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, discuss PSMA-PET's transformative role alongside conventional techniques in prostate cancer imaging.

The authors suggest that metastasis-free survival may serve as a more suitable end point for future clinical trials of radiation therapy in localized prostate cancer.

The UK REIMAGINE study suggests that MRI screening can not only bolster PSA screening, but also has the potential to be the central component of a national prostate cancer screening program.

Prostate cancer survivor Larry Ferguson, DMD, participated in a clinical trial at MUSC Hollings Cancer Center.

The BioProtect Balloon Implant System provides protection to the rectum during radiation therapy for prostate cancer.

In the third installment of this series, Amar U. Kishan, MD, discusses clinical factors to consider in the use of perirectal spacing for patients receiving hypofractionation or SBRT, and outlines unmet needs.

"I'm very pleased that this is now in the armamentarium for us," says Wayne G. Brisbane, MD.

The signatures were derived from the Decipher Genomics Resource for Intelligent Discovery (GRID) database in a retrospective analysis of the phase 2 STREAM study.

Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.

Expert panelists share their perspectives on recent challenges with staffing and turnover in their urology practice and consider how these particular barriers may be overcome, including recruiting and hiring additional advanced practice providers.

The approval of the olaparib/abiraterone regimen was based on an exploratory subgroup analysis of the phase 3 PROpel trial consisting of the 85 patients in the study with BRCA-positive metastatic castration-resistant prostate cancer.

The application is specifically for use of enzalutamide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence and is supported by data from the phase 3 EMBARK trial.

In predicting PCSM at 10 years, the area under the curve with the P-score was 0.93, compared with 0.81 with D’Amico and 0.88 with CAPRA.

Patients in the CONTACT-02 trial were randomly assigned 1:1 to receive cabozantinib plus atezolizumab or a second novel hormonal therapy of either abiraterone and prednisone or enzalutamide.

Key opinion leaders briefly review the key challenges in scheduling leuprolide administration for patients with advanced prostate cancer, including treatment delays, disease breakthrough, and insurance reimbursement, and share solutions to overcome these challenges.

Shared insight on the current state of telehealth and how its use affects treatment selection and followup for patients with advanced prostate cancer.

The study assessed MG-AGEs, SRAGE, GLO1, and AGER, 4 biomarkers that are associated with methyglyoxal.

"Despite challenges, ongoing research and advancements in risk stratification, imaging techniques, and targeted therapies are paving the way for personalized and precision medicine approaches in prostate cancer management," writes Michael S. Cookson, MD, MMHC, FACS.